Efficacy and Safety of Obinutuzumab-chemotherapy Combinations in Front-line Treatment of Follicular Non-Hodgkin Lymphoma During the COVID-19 Pandemic: A Study of KROHEM, the Croatian Cooperative Group for Hematologic Diseases.
Journal
HemaSphere
ISSN: 2572-9241
Titre abrégé: Hemasphere
Pays: United States
ID NLM: 101740619
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
11
06
2022
accepted:
21
10
2022
entrez:
21
11
2022
pubmed:
22
11
2022
medline:
22
11
2022
Statut:
epublish
Résumé
Obinutuzumab (G) has become part of front-line treatment of follicular lymphoma (FL) based on results of a large randomized study. Data on patients treated outside of clinical trials are lacking. We have retrospectively investigated efficacy and safety of G-based immunochemotherapy regimens in 114 patients treated in a real-life setting during a period of 2 years, largely coinciding with the COVID-19 pandemic. The response rate was 93.8%; 18-months overall (OS) and progression-free survival (PFS) were 88% and 84%, respectively. Patients treated with G-cyclophosphamide, vincristine and glucocorticoid + doxorubicine (CHOP) had statistically significantly superior OS and PFS compared to patients treated with G-bendamustine (G-B) (
Identifiants
pubmed: 36407092
doi: 10.1097/HS9.0000000000000807
pmc: PMC9668548
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e807Informations de copyright
Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.
Références
Acta Haematol. 2021;144(2):132-145
pubmed: 32392559
Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):95-102
pubmed: 30581160
Blood. 2013 Aug 8;122(6):981-7
pubmed: 23777769
Oncol Rep. 2022 Jun;47(6):
pubmed: 35506458
J Infect Chemother. 2021 Feb;27(2):387-389
pubmed: 33328135
Lijec Vjesn. 2013 Mar-Apr;135(3-4):63-76
pubmed: 23671972
J Clin Oncol. 2018 Aug 10;36(23):2395-2404
pubmed: 29856692
Oncologist. 2018 Apr;23(4):454-460
pubmed: 29317554
Blood. 2014 May 8;123(19):2944-52
pubmed: 24591201
Ann Oncol. 2017 Jul 1;28(7):1436-1447
pubmed: 28379322
N Engl J Med. 2022 Jun 9;386(23):2188-2200
pubmed: 35443106
J Hematol Oncol. 2021 Oct 14;14(1):168
pubmed: 34649563
Int J Clin Oncol. 2021 Mar;26(3):485-493
pubmed: 33225396
Hemasphere. 2021 Feb 10;5(3):e538
pubmed: 33604516
Croat Med J. 2021 Oct 31;62(5):531-533
pubmed: 34730896
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
N Engl J Med. 2017 Oct 5;377(14):1331-1344
pubmed: 28976863
Lancet. 2013 Apr 6;381(9873):1203-10
pubmed: 23433739
EClinicalMedicine. 2020 Oct;27:100549
pubmed: 33073216
Ann Hematol. 2020 Dec;99(12):2821-2829
pubmed: 32734548